

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:ssptacrs1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 AUG 06 CAS REGISTRY enhanced with new experimental property tags
NEWS 3 AUG 06 FSTA enhanced with new thesaurus edition
NEWS 4 AUG 13 CA/Caplus enhanced with additional kind codes for granted patents
NEWS 5 AUG 20 CA/Caplus enhanced with CAS indexing in pre-1907 records
NEWS 6 AUG 27 Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 7 AUG 27 USPATOLD now available on STN
NEWS 8 AUG 28 CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 9 SEP 07 STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 10 SEP 13 FORIS renamed to SOFIS
NEWS 11 SEP 13 INPADOCDB enhanced with monthly SDI frequency
NEWS 12 SEP 17 CA/Caplus enhanced with printed CA page images from 1967-1998
NEWS 13 SEP 17 Caplus coverage extended to include traditional medicine patents
NEWS 14 SEP 24 EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 15 OCT 02 CA/Caplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 16 OCT 19 BEILSTEIN updated with new compounds
NEWS 17 NOV 15 Derwent Indian patent publication number format enhanced
NEWS 18 NOV 19 WPIX enhanced with XML display format
NEWS 19 NOV 30 ICSD reloaded with enhancements
NEWS 20 DEC 04 LINPADOCDB now available on STN
NEWS 21 DEC 14 BEILSTEIN pricing structure to change
NEWS 22 DEC 17 USPATOLD added to additional database clusters
NEWS 23 DEC 17 IMSDRUGCONF removed from database clusters and STN
NEWS 24 DEC 17 DGENE now includes more than 10 million sequences
NEWS 25 DEC 17 TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS 26 DEC 17 MEDLINE and LMEEDLINE updated with 2008 MeSH vocabulary
NEWS 27 DEC 17 CA/Caplus enhanced with new custom IPC display formats
NEWS 28 DEC 17 STN Viewer enhanced with full-text patent content from USPATOLD
NEWS 29 JAN 02 STN pricing information for 2008 now available

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 14:02:51 ON 10 JAN 2008

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 14:03:02 ON 10 JAN 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 8 JAN 2008 HIGHEST RN 960198-43-0

DICTIONARY FILE UPDATES: 8 JAN 2008 HIGHEST RN 960198-43-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdnoc/properties.html>

=>

Uploading C:\Program Files\STNEXP\Queries\10565453.str



```

chain nodes :
7  8  22 23  24 25 26 27 28 29 30 31 32 33
ring nodes :
1  2  3  4  5  6  9 10 11 12 13 14 15 16 17 18 19 20 21
chain bonds :
2-7  6-8 14-16 19-22 22-23 22-33 23-24 24-25 24-27 25-26 25-31 27-28
28-29 29-30 29-32
ring bonds :
1-2  1-6  2-3  3-4  4-5  4-9  5-6  5-12  9-10 10-11 11-12 11-13 12-15 13-14
14-15 16-17 16-21 17-18 18-19 19-20 20-21
exact/norm bonds :
1-2  1-6  2-3  2-7  3-4  4-5  4-9  5-6  5-12  6-8  9-10 10-11 11-12 11-13 12-15
13-14 14-15 14-16 22-23 22-33 23-24 29-30 29-32
exact bonds :
19-22 24-25 24-27 27-28 28-29
normalized bonds :
16-17 16-21 17-18 18-19 19-20 20-21 25-26 25-31

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS
28:CLASS 29:CLASS 30:CLASS 31:CLASS 32:CLASS 33:CLASS

```

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.

=> s l1 fam ful

FULL SEARCH INITIATED 14:03:26 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 178 TO ITERATE

100.0% PROCESSED 178 ITERATIONS
SEARCH TIME: 00.00.01

101 ANSWERS


L2 101 SEA FAM FUL L1

=> d scan 12

L2 101 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN L-Glutamic acid, N-[4-(3-amino-1,2,5,6,6a,7-hexahydro-1-oxoimidazo[1,5-
f]pteridin-8(9H)-yl)benzoyl]-, sodium salt, (R)-, compd. with
MF α -cyclodextrin and β -cyclodextrin (1:1:1) (9CI)
C42 H70 O35 . C36 H60 O30 . C20 H23 N7 O6 . x Na

CM 1


Absolute stereochemistry.



● x Na


CM 2

Absolute stereochemistry.



Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=> file caplus
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
70.57	70.78

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 14:04:08 ON 10 JAN 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing

of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Jan 2008 VOL 148 ISS 2
FILE LAST UPDATED: 8 Jan 2008 (20080108/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 12

L3 662 L2

=> s 12 and citrate

662 L2

92178 CITRATE

2707 CITRATES

93309 CITRATE

(CITRATE OR CITRATES)

L4 6 L2 AND CITRATE

=> d 14 ibib abs

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:619730 CAPLUS

DOCUMENT NUMBER: 147:39177

TITLE: Stable pharmaceutical compositions of 5,10 methylenetetrahydrofolate

INVENTOR(S): Chen, Andrew X.; Wu, Hongjie; Cantwell, Mark J.; Robbins, Joan M.

PATENT ASSIGNEE(S): Adventrx Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 17pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007064968	A2	20070607	WO 2006-US46142	20061130
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: US 2005-741861P P 20051202

AB The invention provides a stable lyophilized composition of 5,10 methylenetetrahydrofolate (5,10-MTHF) suitable for use in the treatment of cancer and other therapies. The composition comprises 5,10-MTHF in combination with citric acid and ascorbic acid, with the ratio of citric acid to ascorbic acid from about 0.75:1 to about 2.25:1 by weight, and the ratio of total citric acid and ascorbic acid to 5,10-MTHF from about 1.4:1 to about 3.4:1 by weight. Prior to lyophilization, the solution is adjusted to an

essentially neutral pH. Thus, composition was prepared containing 5,10 methylenetetrahydrofolate 100 mg, trisodium citrate 250 mg and ascorbic acid 176 mg.

=> d 14 ibib abs 1-6

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2007:619730 CAPLUS
 DOCUMENT NUMBER: 147:39177
 TITLE: Stable pharmaceutical compositions of 5,10 methylenetetrahydrofolate
 INVENTOR(S): Chen, Andrew X.; Wu, Hongjie; Cantwell, Mark J.; Robbins, Joan M.
 PATENT ASSIGNEE(S): Adventrx Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 17pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007064968	A2	20070607	WO 2006-US46142	20061130
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: US 2005-741861P P 20051202

AB The invention provides a stable lyophilized composition of 5,10 methylenetetrahydrofolate (5,10-MTHF) suitable for use in the treatment of cancer and other therapies. The composition comprises 5,10-MTHF in combination with citric acid and ascorbic acid, with the ratio of citric acid to ascorbic acid from about 0.75:1 to about 2.25:1 by weight, and the ratio of total citric acid and ascorbic acid to 5,10-MTHF from about 1.4:1 to about 3.4:1 by weight. Prior to lyophilization, the solution is adjusted to an essentially neutral pH. Thus, composition was prepared containing 5,10 methylenetetrahydrofolate 100 mg, trisodium citrate 250 mg and ascorbic acid 176 mg.

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2007:197715 CAPLUS
 DOCUMENT NUMBER: 146:247362
 TITLE: Microorganisms with modified primary metabolism increasing the efficiency of biosynthesis of L-methionine
 INVENTOR(S): Zelder, Oskar; Herold, Andrea; Klopprogge, Corinna; Schroeder, Hartwig; Haefner, Stefan; Heinzele, Elmar; Wittmann, Christoph; Kroemer, Jens; Pero, Janice; Yocum, Rogers; Patterson, Thomas; Williams, Mark; Herman, Theron
 PATENT ASSIGNEE(S): BASF A.-G., Germany
 SOURCE: PCT Int. Appl., 327pp.

DOCUMENT TYPE: CODEN: PIXXD2
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: English
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007020295	A2	20070222	WO 2006-EP65460	20060818
WO 2007020295	A3	20070503		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: EP 2005-107609 A 20050818
 EP 2006-114543 A 20060524

AB Methods of increasing the efficiency of biosynthesis of L-methionine, i.e. yield as a function of input energy, by modifying primary metabolism to increase carbon flux through the methionine pathway are described. Data on metabolic fluxes from *Escherichia coli* and *Corynebacterium glutamicum* were used to model metabolic fluxes. Effects of changes in genotype and carbon and sulfur sources were analyzed.

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:1154586 CAPLUS

DOCUMENT NUMBER: 142:79933

TITLE: Stable 5,10-methylene-tetrahydrofolate compounds with citric acid and their lyophilization to prepare drug formulations

INVENTOR(S): Moser, Rudolf; Ammann, Thomas

PATENT ASSIGNEE(S): Merck Eprova AG, Switz.

SOURCE: PCT Int. Appl., 16 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004112761	A2	20041229	WO 2004-EP6944	20040628
WO 2004112761	A3	20050303		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2004248923	A1	20041229	AU 2004-248923	20040628
---------------	----	----------	----------------	----------

CA 2529531	A1	20041229	CA 2004-2529531	20040628
EP 1641460	A2	20060405	EP 2004-763030	20040628
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1842337	A	20061004	CN 2004-80017791	20040628
MX 2005PA14232	A	20060224	MX 2005-PA14232	20051221
IN 2006KN00036	A	20070223	IN 2006-KN36	20060103
US 2007099866	A1	20070503	US 2006-562200	20061108
PRIORITY APPLN. INFO.:			CH 2003-1123	A 20030626
			WO 2004-EP6944	W 20040628

AB The invention relates to 5,10-methylene-(6R)-,-(6S)-or (6R,S)-tetrahydrofolate (MTHF) pharmaceutical compds. whose stability is due to the adjustment thereof to a basic pH value and to a simultaneous citrate use. Said stabilization is self-producible in the absence of a reducing agent. Said invention is particularly suitable for preparing lyophilization solution or lyophilizates or dry powders and dry mixts. since the stable MTHF solns. can be filled at the high concentration thereof into corresponding recipients like, for example vials, ampoules etc. Said lyophilizates are surprisingly storable and stable. They are easily reconstituted by adding water or aqueous solns., thereby providing diluted injection solns. ready for use with an excellent stability. Said invention also makes it possible to produce highly concentrated calcium or acid MTHF salts, even difficult-to-dissolve, in the form of isotonic physiol. compatible solns. Thus 9900 mL water was saturated with argon gas and 421.9 g citric acid were dissolved. 232.0 G 5,10-methylene-(6R,6S)-tetrahydrofolic acid calcium salt was added; pH was set to 8.0 with sodium hydroxide, during which the salt was completely dissolved; the pH was adjusted to 8.5,. The solution was filled into glass vials and freeze-dried; vials that contained 5,10-methylene-(6R,6S)-tetrahydrofolic acid were obtained.

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2008 ACS ON STN

ACCESSION NUMBER: 2002:778164 CAPLUS
DOCUMENT NUMBER: 137:275029
TITLE: Crystal structure of ketopantoate
hydroxymethyltransferase and applications to drug
design
INVENTOR(S): Blundell, Tom Leon; Abell, Christopher; Inoue,
Tsuyoshi; Von Delft, Frank
PATENT ASSIGNEE(S): Astex Technology Limited, UK
SOURCE: PCT Int. Appl., 367 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2002079460	A2	20021010	WO 2002-GB1405	20020402
WO 2002079460	A3	20030424		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2004053385	A1	20040318	US 2001-820745	20010330

AU 2002251191 A1 20021015 AU 2002-251191 20020402
 EP 1373482 A2 20040102 EP 2002-720121 20020402
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 PRIORITY APPLN. INFO.: US 2001-820745 A 20010330
 WO 2002-GB1405 W 20020402
 AB The invention provides a crystal of ketopantoate hydroxymethyltransferase
 (KPHMT) from E. coli. The crystal may be characterized by the three
 dimensional atomic coordinates of the crystal are disclosed. The invention
 also provides the use of such crystals and the three dimensional atomic
 coordinates in computer modeling applications, for example in drug design
 and drug discovery.
 L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2001:885728 CAPLUS
 DOCUMENT NUMBER: 136:11204
 TITLE: Composition for the treatment and/or the prevention of
 osteoporosis and/or inflammatory joint diseases
 INVENTOR(S): Buchholz, Herwig; Meduski, Jerzy; Frohne, Marcus
 PATENT ASSIGNEE(S): Merck Patent Gmbh, Germany
 SOURCE: PCT Int. Appl., 23 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001091734	A2	20011206	WO 2001-EP5753	20010519
WO 2001091734	A3	20021205		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2410885	A1	20011206	CA 2001-2410885	20010519
EP 1286667	A2	20030305	EP 2001-953150	20010519
EP 1286667	B1	20060614		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003534373	T	20031118	JP 2001-587750	20010519
BR 2001011210	A	20031216	BR 2001-11210	20010519
AT 329587	T	20060715	AT 2001-953150	20010519
ES 2266220	T3	20070301	ES 2001-1953150	20010519
US 2003139354	A1	20030724	US 2002-296972	20021202
US 6812215	B2	20041102		
PRIORITY APPLN. INFO.:				
			US 2000-208572P	P 20000602
			WO 2001-EP5753	W 20010519
AB Comps. and pharmaceutical comps. are described which comprise: a component A comprising one or more flavonol glycosides, a component B comprising one or more tetrahydrofolic acid comps., a component C comprising one or more calcium supplements, and a component D comprising one or more magnesium supplements. Methods of using such comps. and pharmaceutical comps. to treat and/or prevent osteoporosis and/or an inflammatory joint disease are also described. An oral formulation contained isoquercetin 500 mg, Ca 5-methyltetrahydrofolate 800 µg, Ca				

citrate tetrahydrate 4000 mg, and Mg chloride hexahydrate 3000 mg.

L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1997:532205 CAPLUS

DOCUMENT NUMBER: 127:189892

TITLE: Food and vitamin preparations containing the natural isomer of reduced folates

INVENTOR(S): Bailey, Steven W.; Ayling, June E.

PATENT ASSIGNEE(S): South Alabama Medical Science Foundation, USA; Bailey, Steven W.; Ayling, June E.

SOURCE: PCT Int. Appl., 31 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9727764	A1	19970807	WO 1997-US1870	19970131
W: AU, CA, CN, JP, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2243981	C	19970807	CA 1997-2243981	19970131
CA 2243981	A1	19970807		
AU 9722602	A	19970822	AU 1997-22602	19970131
AU 722050	B2	20000720		
EP 877563	A1	19981118	EP 1997-905791	19970131
EP 877563	B1	20040331		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CN 1209729	A	19990303	CN 1997-191951	19970131
CN 1122456	B	20031001		
JP 20000505286	T	20000509	JP 1997-527939	19970131
JP 3602141	B2	20041215		
AT 262799	T	20040415	AT 1997-905791	19970131
EP 1425978	A1	20040609	EP 2004-3374	19970131
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PT 877563	T	20040831	PT 1997-905791	19970131
ES 2218662	T3	20041116	ES 1997-905791	19970131
US 5997915	A	19991207	US 1998-117586	19980731
US 6254904	B1	20010703	US 1999-418649	19991015
AU 767242	B2	20031106	AU 2000-66488	20001012
US 2001046533	A1	20011129	US 2001-888798	20010625
US 6451360	B2	20020917		
US 2002150653	A1	20021017	US 2002-174272	20020618
US 6808725	B2	20041026		
US 2002176912	A1	20021128	US 2002-196118	20020716
US 6673381	B2	20040106		
US 2004219262	A1	20041104	US 2003-748116	20031230
US 7172778	B2	20070206		
US 2007207136	A1	20070906	US 2007-702006	20070203
PRIORITY APPLN. INFO.:			US 1996-10898P	P 19960131
			AU 1997-22602	A3 19970131
			EP 1997-905791	A3 19970131
			WO 1997-US1870	W 19970131
			US 1998-117586	A1 19980731
			US 1999-418649	A1 19991015
			US 2001-888798	A1 20010625
			US 2002-196118	A1 20020716
			US 2003-748116	A1 20031230

AB A composition for human or animal consumption for supplying folate which

includes a natural isomer of reduced folate, such as (6S)-tetrahydrofolic acid, 5-methyl-(6S)-tetrahydrofolic acid, 5-formyl-(6S)-tetrahydrofolic acid, 10-formyl-(6R)-tetrahydrofolic acid, 5,10-methylene-(6R)-tetrahydrofolic acid, 5,10-methenyl-(6R)-tetrahydrofolic acid, 5-formimino-(6S)-tetrahydrofolic acid, and their polyglutamyl derivs. is disclosed. Such compns. include multivitamin prepn. (with or without minerals and other nutrients); breakfast foods such as prepared cereals, toaster pastries and breakfast bars; infant formulas; dietary supplements and complete diet and weight-loss formulas and bars; animal feed (for example pet foods) and animal feed supplements (such as for poultry feed). The amount of the natural isomer of a reduced folate in a composition for human consumption can range between about 5 % and about 200 % of the daily requirement for folic acid per serving or dose.

=> d his

(FILE 'HOME' ENTERED AT 14:02:51 ON 10 JAN 2008)

FILE 'REGISTRY' ENTERED AT 14:03:02 ON 10 JAN 2008

L1 STRUCTURE UPLOADED

L2 101 S L1 FAM FUL

FILE 'CAPLUS' ENTERED AT 14:04:08 ON 10 JAN 2008

L3 662 S L2

L4 6 S L2 AND CITRATE

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION

FULL ESTIMATED COST

26.81	97.59
-------	-------

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION

CA SUBSCRIBER PRICE

-5.60	-5.60
-------	-------

STN INTERNATIONAL LOGOFF AT 14:09:24 ON 10 JAN 2008